(MDVN:Consolidated Issue Listed on NASDAQ Global Select )
Pablo D. T. Valenzuela Ph.D.
Member of Scientific & Clinical Advisory Board,Medivation, Inc.
|Age||Total Calculated Compensation||This person is connected to 29 board members in 4 different organizations across 4 different industries.|
See Board Relationships
Dr. Pablo D. T. Valenzuela, Ph.D., is a Founder and President at Bios Chile. He is the Co-founder and Head of Research and Development of Grupo Bios, Austral Biologicals, Andes Bioscience, Ventra Bioscience, Fundación Ciencia Para la Vida, and at Chiron Corporation where he also served as the Senior Vice President, Biological Research and Development until 2000. He serves as a Director of Ventria Bioscience, Inc. Dr. Valenzuela serves as a Member of Scientific & Clinical ...
525 Market StreetPhone: 415-543-3470
San Francisco, California 94105
Board Members Memberships*
President of the Board
Director, Member of Audit Committee, Member of Compensation Committee, and Member of Nominating & Corporate Governance Committee
University of California-San Francisco
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Harvey J. Berger M.D.||Principal Founder, Chairman, Chief Executive Officer and President|
Ariad Pharmaceuticals Inc.
|Clay B. Siegall Ph.D.||Co-Founder, Chairman, Chief Executive Officer and President|
Seattle Genetics, Inc.
|Shailesh Ayyangar B.V.Fc & A.H., P.G.D.M.||Managing Director, Vice President of South Asia, Global Operations, Executive Director, Member of Audit Committee and Member of Corporate Social Responsibility Committee|
Sanofi India Limited
|Aijaz Tobaccowalla||Managing Director, Director, Member of Board Administrative & Share Transfer Committee, Member of Nomination & Remuneration Committee, Member of Corporate Social Responsibility Committee and Member of Audit Committee|
|Michael L. Babich||Chief Executive Officer, President and Director|
INSYS Therapeutics, Inc.
|$889.2K||Compensation as of Fiscal Year 2014.|